CA2161808A1 - Bmp-11 compositions - Google Patents

Bmp-11 compositions

Info

Publication number
CA2161808A1
CA2161808A1 CA002161808A CA2161808A CA2161808A1 CA 2161808 A1 CA2161808 A1 CA 2161808A1 CA 002161808 A CA002161808 A CA 002161808A CA 2161808 A CA2161808 A CA 2161808A CA 2161808 A1 CA2161808 A1 CA 2161808A1
Authority
CA
Canada
Prior art keywords
proteins
bmp
useful
disclosed
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002161808A
Other languages
French (fr)
Other versions
CA2161808C (en
Inventor
Anthony J. Celeste
John M. Wozney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Anthony J. Celeste
John M. Wozney
Genetics Institute, Inc.
Genetics Institute, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthony J. Celeste, John M. Wozney, Genetics Institute, Inc., Genetics Institute, Llc filed Critical Anthony J. Celeste
Publication of CA2161808A1 publication Critical patent/CA2161808A1/en
Application granted granted Critical
Publication of CA2161808C publication Critical patent/CA2161808C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Abstract

Purified BMP-11 proteins and processes for producing them are disclosed.
Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may be useful in regulating follicle stimulating hormone, such as for contraception. In addition, the proteins may be useful for the induction of bone, cartilage and/or other connective tissue.
CA002161808A 1993-05-12 1994-05-12 Bmp-11 compositions Expired - Fee Related CA2161808C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6146493A 1993-05-12 1993-05-12
US08/061,464 1993-05-12
PCT/US1994/005288 WO1994026892A1 (en) 1993-05-12 1994-05-12 Bmp-11 compositions

Publications (2)

Publication Number Publication Date
CA2161808A1 true CA2161808A1 (en) 1994-11-24
CA2161808C CA2161808C (en) 2008-08-05

Family

ID=22035966

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002161808A Expired - Fee Related CA2161808C (en) 1993-05-12 1994-05-12 Bmp-11 compositions

Country Status (17)

Country Link
US (7) US5639638A (en)
EP (4) EP1770161A3 (en)
JP (2) JP3681069B2 (en)
KR (1) KR100227406B1 (en)
AT (2) ATE343635T1 (en)
AU (1) AU678582B2 (en)
BR (1) BR9406715A (en)
CA (1) CA2161808C (en)
DE (2) DE69434875T2 (en)
DK (2) DK0698094T3 (en)
ES (2) ES2274157T3 (en)
FI (1) FI119696B (en)
HK (1) HK1060898A1 (en)
NO (1) NO320119B1 (en)
OA (1) OA10191A (en)
PT (2) PT1378572E (en)
WO (1) WO1994026892A1 (en)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE20004692U1 (en) 2000-03-14 2001-07-26 Sofamor Danek Gmbh Vertebral implant for screwing into an intervertebral space
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US20080070842A1 (en) * 1991-11-04 2008-03-20 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
DE69233022T2 (en) * 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6465239B1 (en) * 1993-03-19 2002-10-15 The John Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
JP3681069B2 (en) * 1993-05-12 2005-08-10 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー BMP-11 composition
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
CA2176942C (en) * 1993-12-07 2011-11-01 Anthony J. Celeste Bmp-12, bmp-13 and tendon-inducing compositions thereof
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US7332575B2 (en) * 1994-03-18 2008-02-19 The Johns Hopkins University School Of Medicine Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species
US5906827A (en) † 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
CA2194660C (en) * 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US5846770A (en) * 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US5645084A (en) * 1995-06-07 1997-07-08 Danek Medical, Inc. Method for spinal fusion without decortication
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
EP2289536A1 (en) 1995-06-05 2011-03-02 Genetics Institute, LLC Use of bone morphogenetic proteins for healing and repair of connective tissue attachment
US5902785A (en) * 1995-06-06 1999-05-11 Genetics Institute, Inc. Cartilage induction by bone morphogenetic proteins
US5700774A (en) * 1996-03-26 1997-12-23 Genetics Institute, Inc. Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
US5965403A (en) 1996-09-18 1999-10-12 Genetics Institute, Inc. Nucleic acids encoding bone morphogenic protein-16 (BMP-16)
US6037519A (en) * 1997-10-20 2000-03-14 Sdgi Holdings, Inc. Ceramic fusion implants and compositions
CA2283461A1 (en) * 1997-03-14 1998-09-17 Uab Research Foundation Adenoviral vectors with modified tropism
US7041641B2 (en) 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
CA2291514C (en) 1997-05-30 2011-07-12 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
US5972368A (en) 1997-06-11 1999-10-26 Sdgi Holdings, Inc. Bone graft composites and spacers
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6696260B1 (en) * 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
AU8666398A (en) * 1997-08-01 1999-02-22 Johns Hopkins University School Of Medicine, The Methods to identify growth differentiation factor (gdf) receptors
US20020052026A1 (en) 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
US6511509B1 (en) 1997-10-20 2003-01-28 Lifenet Textured bone allograft, method of making and using same
AU1276399A (en) * 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
US6027917A (en) 1997-12-10 2000-02-22 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-17 and BMP-18 compositions
US20030036629A1 (en) * 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
WO2000006716A1 (en) * 1998-07-28 2000-02-10 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
AU5341999A (en) 1998-08-06 2000-02-28 Sdgi Holdings, Inc. Composited intervertebral bone spacers
US6849255B2 (en) * 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
EP1181041A2 (en) * 1999-04-30 2002-02-27 Curis, Inc. Morphogen-induced enhancement of fertility
DK1244388T3 (en) 1999-12-06 2007-05-14 Warsaw Orthopedic Inc Device for treating intervertebral discs
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
WO2002056800A2 (en) 2000-12-08 2002-07-25 Osteotech, Inc. Implant for orthopedic applications
US6752831B2 (en) 2000-12-08 2004-06-22 Osteotech, Inc. Biocompatible osteogenic band for repair of spinal disorders
US7141392B2 (en) 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
US6942853B2 (en) 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
EP1790726B1 (en) * 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
KR100420798B1 (en) * 2001-02-10 2004-03-02 (주)알에이싸이언스 Peptide vector
DE60226321T2 (en) * 2001-06-01 2009-07-09 Wyeth COMPOSITIONS FOR THE SYSTEMIC ADMINISTRATION OF SEQUENCES THAT CODE FOR BONE MORPHOGENESIS PROTEINS
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6798160B2 (en) * 2001-11-02 2004-09-28 Honda Giken Kogyo Kabushiki Kaisha Electric working machine
CN1301757C (en) * 2001-11-27 2007-02-28 多喜兰株式会社 Implant material and process for producing the same
CH695985A5 (en) * 2002-01-21 2006-11-15 Straumann Holding Ag Surface-modified implants.
CA2476887A1 (en) 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
PL374966A1 (en) * 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
TWI282283B (en) * 2002-05-17 2007-06-11 Wyeth Corp Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
EP1542711A4 (en) 2002-08-13 2009-07-01 Wyeth Corp PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR s PROTEINS
ES2344734T3 (en) * 2002-09-16 2010-09-06 Johns Hopkins University ACTIVATION OF MYOSTATIN BY METALOPROTEASE, AND METHODS TO MODULATE THE ACTIVITY OF MYOSTATIN.
AR047392A1 (en) 2002-10-22 2006-01-18 Wyeth Corp NEUTRALIZATION OF ANTIBODIES AGAINST GDF 8 AND ITS USE FOR SUCH PURPOSES
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
EP1635870A2 (en) * 2003-06-02 2006-03-22 Wyeth Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
ES2282904T3 (en) * 2003-09-12 2007-10-16 Wyeth SOLID BARS OF INJECTABLE CALCIUM PHOSPHATE FOR THE SUPPLY OF OSTEOGENIC PROTEINS.
PT1737734E (en) 2004-03-10 2010-11-11 Scil Technology Gmbh Coated implants, their manufacturing and use thereof
US7575751B2 (en) 2004-04-27 2009-08-18 Research Development Foundation Activin-A mutants
EP2298335B1 (en) 2004-05-25 2014-09-03 Stryker Corporation Use of OP-1 for treating cartilage defects
US7749268B2 (en) 2004-05-26 2010-07-06 Warsaw Orthopedic, Inc. Methods for treating the spine
WO2006020884A2 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US20060166251A1 (en) * 2005-01-26 2006-07-27 Archambault Joanne M Use of sFRPs as markers of BMP activity
CN101137906A (en) * 2005-03-23 2008-03-05 惠氏公司 Detection of an immune response to gdf-8 modulating agents
AU2006230434A1 (en) * 2005-03-30 2006-10-05 Wyeth Methods for stimulating hair growth by administering BMPs
US8506646B2 (en) 2005-04-29 2013-08-13 Warsaw Orthopedic, Inc. Multi-purpose medical implant devices
US20060247790A1 (en) * 2005-04-30 2006-11-02 Mckay William F Shaped osteochondral grafts and methods of using same
CN101277976B (en) 2005-10-06 2012-04-11 伊莱利利公司 Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
EP1991282B1 (en) 2006-02-09 2013-06-19 BioMimetic Therapeutics, LLC Compositions and methods for treating bone
CA2652549A1 (en) 2006-05-17 2007-12-13 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
ES2664229T3 (en) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Compositions and methods of biomatrix-PDGF for the treatment of rotator cuff injuries
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US8524265B2 (en) 2006-08-17 2013-09-03 Warsaw Orthopedic, Inc. Medical implant sheets useful for tissue regeneration
CA2661836A1 (en) 2006-09-05 2008-03-13 Eli Lilly And Company Anti-myostatin antibodies
JP2008104401A (en) * 2006-10-25 2008-05-08 Kyoto Univ In-vitro proliferation method of spermatogonial stem cell
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
JP5452230B2 (en) 2006-12-21 2014-03-26 ストライカー コーポレイション Sustained release formulations comprising biological agent crystals, polymer gels and particle suspensions
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (en) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 Be contained in the protein formulations of the GDF-5 in the acidic aqueous solution
EP2268302B1 (en) 2008-02-13 2014-04-09 Keith Hruska Bmp-7 for use in treating neointimal hyperplasia
EP2276458A1 (en) 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
CN102231992B (en) 2008-09-09 2015-05-20 生物模拟治疗公司 Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
JP5819733B2 (en) 2009-02-12 2015-11-24 ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Peripheral administration of TGF-β superfamily member-containing protein for systemic treatment of disorders and diseases
EP2396026A2 (en) 2009-02-12 2011-12-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
US8609127B2 (en) 2009-04-03 2013-12-17 Warsaw Orthopedic, Inc. Medical implant with bioactive material and method of making the medical implant
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
US9399086B2 (en) 2009-07-24 2016-07-26 Warsaw Orthopedic, Inc Implantable medical devices
US20110224138A1 (en) 2009-09-09 2011-09-15 Julie Krop Methods for treating pain induced by injuries and diseases of an articular joint
WO2011035094A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
JP2013514811A (en) 2009-12-22 2013-05-02 ストライカー コーポレイション BMP-7 mutant with reduced immunogenicity
MX2012009687A (en) 2010-02-22 2012-11-29 Biomimetic Therapeutics Inc Platelet-derived growth factor compositions and methods for the treatment of tendinopathies.
WO2011139594A2 (en) 2010-04-27 2011-11-10 Medtronic, Inc. Artificial bursa for intra-articular drug delivery
SG187589A1 (en) 2010-08-20 2013-03-28 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
WO2012177759A1 (en) 2011-06-20 2012-12-27 Rdc Holdings, Llc System and method for repairing joints
US8998925B2 (en) 2011-06-20 2015-04-07 Rdc Holdings, Llc Fixation system for orthopedic devices
EP2828289B1 (en) * 2012-03-19 2020-02-26 The Brigham and Women's Hospital, Inc. Growth differentiation factor (gdf) 11 for treatment of age-related cardiovascular condition
WO2014012101A1 (en) 2012-07-13 2014-01-16 Trustees Of Tufts College Silk powder compaction for production of constructs with high mechanical strength and stiffness
EP2956545A4 (en) * 2013-02-15 2016-07-20 Joslin Diabetes Ct Thymic regeneration
EP2983694B1 (en) * 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
WO2014172692A1 (en) 2013-04-19 2014-10-23 Theracell, Inc. Demineralized bone fibers having controlled geometry and shapes and methods thereof
US20160287667A1 (en) * 2013-11-08 2016-10-06 President And Fellows Of Harvard College Methods and compositions for rejuvenating neuromuscular junctions
WO2015073396A1 (en) 2013-11-12 2015-05-21 The Brigham And Women's Hospital, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
US10610366B2 (en) 2015-01-29 2020-04-07 Theracell, Inc. Demineralized bone fiber composition for use in minimally invasive surgery
KR20170138436A (en) 2015-03-17 2017-12-15 이스티튜토 바이오키미코 이탈리아노 지오바니 로렌치니 에스.피.에이. Purification of osteogenic protein (BPM)
KR20180019646A (en) 2015-06-17 2018-02-26 워쏘우 오르쏘페딕 인코포레이티드 Implant containing oxysterol and method of use
WO2017075055A1 (en) 2015-10-26 2017-05-04 President And Fellows Of Harvard College Reduced and oxidized polysaccharides and methods of use thereof
EP3399998B1 (en) 2016-01-06 2021-07-21 President and Fellows of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
KR101810385B1 (en) * 2016-02-04 2017-12-20 주식회사 강스템바이오텍 Composition comprising GDF11 and uses thereof
US10688222B2 (en) 2016-11-21 2020-06-23 Warsaw Orthopedic, Inc. Lyophilized moldable implants containing an oxysterol
US10639157B2 (en) 2017-03-14 2020-05-05 Theracell, Inc. Demineralized bone fiber composition for use in minimally invasive surgery
US11464888B2 (en) 2017-06-12 2022-10-11 Warsaw Orthopedic, Inc. Moldable formulations containing an oxysterol in an acellular tissue matrix
KR101893339B1 (en) * 2017-09-19 2018-08-31 주식회사 강스템바이오텍 Composition comprising GDF11 and uses thereof
US11103618B2 (en) 2018-02-22 2021-08-31 Warsaw Orthopedic, Inc. Demineralized bone matrix having improved handling characteristics
CN109097425B (en) * 2018-08-28 2022-06-07 浙江康嘉基因技术有限公司 Polypeptide and application of polypeptide as influenza vaccine immunologic adjuvant
US11498880B2 (en) 2019-07-26 2022-11-15 Warsaw Orthopedic, Inc. Calcium phosphate granules and methods of making them

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
CA1341617C (en) 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
JP2540509B2 (en) 1984-07-06 1996-10-02 サンド・アクチエンゲゼルシヤフト Lymphokine production and purification
ATE128715T1 (en) 1984-07-16 1995-10-15 Celtrix Pharma POLYPEPTIDE-INDUCING FACTORS IN BONE AND CARTILAGE.
EP0177343B1 (en) 1984-10-05 1992-07-22 Genentech, Inc. Dna, cell cultures and methods for the secretion of heterologous proteins and periplasmic protein recovery
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US4798885A (en) 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
NZ231899A (en) * 1985-10-03 1991-07-26 Genentech Inc Human or porcine inhibin peptide compositions and dna encoding them
US4737578A (en) * 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5108922A (en) 1986-07-01 1992-04-28 Genetics Institute, Inc. DNA sequences encoding BMP-1 products
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5106748A (en) 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5187076A (en) 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5041538A (en) * 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5168150A (en) 1988-03-17 1992-12-01 Electronique Serge Dassault Device for the processing of a magnetic-track ticket, especially an air transport ticket
US5071834A (en) 1988-09-16 1991-12-10 Genentech, Inc. Purified activin B composition
US5166190A (en) * 1990-01-08 1992-11-24 Genentech, Inc. Method for increasing fertility in males
ES2168091T3 (en) 1990-05-16 2002-06-01 Genetics Inst OSEA AND CARTILAGINOUS INDUCTION PROTEINS.
US5168050A (en) * 1990-05-24 1992-12-01 Genentech, Inc. Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
WO1992005199A1 (en) * 1990-09-26 1992-04-02 Genetics Institute, Inc. Bmp-5 derivatives
JP3356775B2 (en) * 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド Use of osteogenic proteins for bone repair by co-combination with TGF-β
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
CA2102808A1 (en) * 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
DE69233022T2 (en) * 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE
ES2201059T5 (en) 1992-07-31 2007-11-01 Curis, Inc. REGENERATION AND REPAIR OF NERVES INDUCED BY MORPHOGENS.
EP0690873B1 (en) * 1993-03-19 2003-06-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
CA2161807A1 (en) * 1993-05-12 1994-11-24 Anthony J. Celeste Bmp-10 compositions
JP3681069B2 (en) * 1993-05-12 2005-08-10 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー BMP-11 composition
KR100329409B1 (en) * 1993-08-26 2002-03-20 브루스 엠. 에이센, 토마스 제이 데스로저 Neural regeneration using human bone morphogenetic proteins
CA2194660C (en) * 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US5545616A (en) * 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
ATE493141T1 (en) 1996-03-22 2011-01-15 Stryker Corp METHOD FOR IMPROVED FUNCTIONAL RECOVERY OF MOTOR COORDINATION, LANGUAGE OR SENSORY PERCEPTION AFTER CNS TRAUMA OR ISCHEMIA
JP3361278B2 (en) 1997-12-26 2003-01-07 シャープ株式会社 Reflection type liquid crystal display device, method for manufacturing the same, and method for manufacturing circuit board
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]

Also Published As

Publication number Publication date
US5639638A (en) 1997-06-17
EP1770161A3 (en) 2008-04-23
KR960701996A (en) 1996-03-28
PT698094E (en) 2004-05-31
EP2272959A1 (en) 2011-01-12
US20030166910A1 (en) 2003-09-04
OA10191A (en) 1996-12-18
DE69433530T2 (en) 2005-01-05
WO1994026892A1 (en) 1994-11-24
JP3681069B2 (en) 2005-08-10
HK1060898A1 (en) 2004-08-27
DK0698094T3 (en) 2004-05-03
FI955419A0 (en) 1995-11-10
FI955419A (en) 1996-01-08
NO320119B1 (en) 2005-10-31
US6340668B1 (en) 2002-01-22
JP2005046155A (en) 2005-02-24
CA2161808C (en) 2008-08-05
ES2213745T3 (en) 2004-09-01
US5700911A (en) 1997-12-23
US7175997B2 (en) 2007-02-13
ATE258984T1 (en) 2004-02-15
JPH09501304A (en) 1997-02-10
NO954492D0 (en) 1995-11-08
AU6910594A (en) 1994-12-12
EP1770161A2 (en) 2007-04-04
EP1378572B1 (en) 2006-10-25
NO954492L (en) 1995-11-08
DE69433530D1 (en) 2004-03-11
EP0698094A1 (en) 1996-02-28
PT1378572E (en) 2007-01-31
US6437111B1 (en) 2002-08-20
EP0698094B1 (en) 2004-02-04
ATE343635T1 (en) 2006-11-15
ES2274157T3 (en) 2007-05-16
AU678582B2 (en) 1997-06-05
US20060172391A1 (en) 2006-08-03
DE69434875D1 (en) 2006-12-07
EP1378572A1 (en) 2004-01-07
DK1378572T3 (en) 2007-02-05
FI119696B (en) 2009-02-13
US20030083252A1 (en) 2003-05-01
DE69434875T2 (en) 2007-09-06
KR100227406B1 (en) 1999-12-01
BR9406715A (en) 1996-02-06

Similar Documents

Publication Publication Date Title
CA2161808A1 (en) Bmp-11 compositions
CA2108770A1 (en) Bmp-9 compositions
WO1999024058A3 (en) Neuronal uses of bmp-11
DE69433742D1 (en) BMP-10 COMPOSITIONS
EP1230930A3 (en) Bmp-9 compositions
CA2265508A1 (en) Bone morphogenetic protein-16 (bmp-16) compositions
CA2030518A1 (en) Osteoinductive compositions
EP2261232A3 (en) Inhibitors of caspases
AP9600782A0 (en) Recombinant il,4 antibodies useful in treatment of il,4 mediated disorders
EP0760849A4 (en) Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
CA2120153A1 (en) Recombinant immunotoxins
AU3711597A (en) A novel galanin receptor
MY114769A (en) Non-splicing variants of gp350/220
CA2138793A1 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
AU2415599A (en) Rantes mutants and therapeutic applications thereof
EP0723016A3 (en) Activating factor of leukocytes
AU3577589A (en) Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinaceous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140513